Sugi Predict

Sugi Predict / Compounds / SCHEMBL2674841

SCHEMBL2674841

SCHEMBL2674841

N=CCOCc1ccccc1

nearest known ligand 0.63

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 1/20 0.61
▸ IDO1 P14902 1/20 0.44
▸ AGXT P21549 1/20 0.43
▸ MAOB P27338 1/20 0.42
▸ ALOX5 P09917 1/20 0.41
▸ CA1 P00915 4/20 0.41
▸ CA2 P00918 2/20 0.41
▸ CA7 P43166 2/20 0.41
▸ CA9 Q16790 2/20 0.41
▸ KDM4E B2RXH2 1/20 0.41
▸ POLB P06746 1/20 0.41
▸ TACR1 P25103 2/20 0.40
▸ NAAA Q02083 1/20 0.38
▸ TK1 P04183 1/20 0.38
▸ ALDH1A1 P00352 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1524098 0.81 TSHR (0.67) TSHRIDO1AGXTMAOBALOX5
SCHEMBL4574153 0.81 TSHR (0.67) TSHRIDO1AGXTALOX5CA1
SCHEMBL1524411 0.81 TSHR (0.67) TSHRIDO1AGXTMAOBALOX5
SCHEMBL6941005 0.81 TSHR (0.67) TSHRIDO1AGXTALOX5CA1
SCHEMBL1524101 0.81 TSHR (0.67) TSHRIDO1AGXTMAOBALOX5
SCHEMBL4069935 0.80 TSHR (0.58) TSHRIDO1AGXTMAOBALOX5
Ammonia Solution, Strong SCHEMBL7095980 0.79 TSHR (0.64) TSHRIDO1AGXTMAOBALOX5
SCHEMBL15153296 0.77 TSHR (0.61) TSHRIDO1AGXTALOX5CA1
SCHEMBL798003 0.77 TSHR (0.61) TSHRIDO1AGXTALOX5CA1
SCHEMBL18585644 0.77 TSHR (0.61) TSHRIDO1AGXTMAOBALOX5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090105292-A9 Glucocorticoid Receptor Modulator Compounds and Methods LIGAND PHARMACEUTICALS INCORPORATED (US) 2009-04-23 — — US claimed
US-20070281959-A1 Glucocorticoid receptor modulator compounds and methods LIGAND PHARMACEUTICALS INCORPORATED (US) 2007-12-06 — — US claimed
EP-3048098-A1 N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS AbbVie Bahamas Limited (BS) 2016-07-27 — — EP disclosed
EP-1685119-B1 N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS ABBVIE BAHAMAS LTD (BS) 2016-03-09 — — EP disclosed
US-9045444-B2 Apoptosis promoters ABBVIE INC. (US) 2015-06-02 — — US disclosed
US-20140187531-A1 APOPTOSIS PROMOTERS ABBVIE INC. (US) 2014-07-03 — — US disclosed
EP-2308812-B1 N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS ABBVIE BAHAMAS LTD (BS) 2014-02-26 — — EP disclosed
US-8614318-B2 Apoptosis promoters ABBVIE INC. (US) 2013-12-24 — — US disclosed
US-20130190488-A1 APOPTOSIS PROMOTERS ABBOTT LABORATORIES (US) 2013-07-25 — — US disclosed
US-8354404-B2 Apoptosis promoters ABBOTT LABORATORIES (US) 2013-01-15 — — US disclosed
US-8173811-B2 Apoptosis promoters ABBOTT LABORATORIES (US) 2012-05-08 — — US disclosed
US-20070015787-A1 Apoptosis promoters ABBVIE INC. 2007-01-18 — — US disclosed
US-20060258657-A1 Apoptosis promoters ABBVIE INC. 2006-11-16 — — US disclosed
EP-1718653-A1 GLUCOCORTICOID RECEPTOR MODULATOR COMPOUNDS AND METHODS- UTILITY Ligand Pharmaceuticals Inc. (US) 2006-11-08 — — EP disclosed
EP-1685119-A1 N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS Abbott Laboratories (US) 2006-08-02 — — EP disclosed
US-20060128706-A1 Apoptosis promoters ABBVIE INC. 2006-06-15 — — US disclosed
WO-2005082909-A1 GLUCOCORTICOID RECEPTOR MODULATOR COMPOUNDS AND METHODS- UTILITY LIGAND PHARMACEUTICALS INCORPORATED (US) 2005-09-09 — — WO disclosed
US-20050159427-A1 N-acylsulfonamide apoptosis promoters ABBOTT LABORATORIES 2005-07-21 — — US disclosed
WO-2005049593-A2 N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS ABBOTT LABORATORIES (US) 2005-06-02 — — WO disclosed
WO-2005049594-A1 N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS ABBOTT LABORATORIES (US) 2005-06-02 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060128706-A1 Apoptosis promoters BAX, BCL2, API5 TSHR 4124/4885IDO1 4761/4885AGXT 3199/4885
US-20130190488-A1 APOPTOSIS PROMOTERS BAX, BCL2, API5 TSHR 4124/4885IDO1 4761/4885AGXT 3199/4885
US-20070015787-A1 Apoptosis promoters BAX, BCL2, API5 TSHR 4124/4885IDO1 4761/4885AGXT 3199/4885
US-20060258657-A1 Apoptosis promoters BAX, BCL2, API5 TSHR 4124/4885IDO1 4761/4885AGXT 3199/4885
US-20050159427-A1 N-acylsulfonamide apoptosis promoters BAX, API5, CCAR2 TSHR 4317/4885IDO1 4602/4885AGXT 2331/4885
US-20140187531-A1 APOPTOSIS PROMOTERS BAX, BCL2, API5 TSHR 4124/4885IDO1 4761/4885AGXT 3199/4885
US-20090105292-A9 Glucocorticoid Receptor Modulator Compounds and Methods NR3C1, NR3C2, MC2R TSHR 244/4885IDO1 3384/4885AGXT 2272/4885
US-20070281959-A1 Glucocorticoid receptor modulator compounds and methods NR3C1, NR3C2, MC2R TSHR 244/4885IDO1 3384/4885AGXT 2272/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.